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Key Points
Question
Does the use of 3-dimensional, virtual reality models for planning robotic-assisted partial nephrectomy improve
surgical outcomes?
Findings
In this single-blind randomized clinical trial involving 92 patients, the use of 3-dimensional virtual reality models
reduced the operative time, estimated blood loss, clamp time, and length of hospital stay.
Meaning
This randomized clinical trial demonstrates key outcomes improvements when using 3-dimensional, virtual reality
models to plan robotic-assisted partial nephrectomy.

Abstract
Importance
Planning complex operations such as robotic-assisted partial nephrectomy requires surgeons to review 2-dimensional
computed tomography or magnetic resonance images to understand 3-dimensional (3-D), patient-specific anatomy.
Objective
To determine surgical outcomes for robotic-assisted partial nephrectomy when surgeons reviewed 3-D virtual reality
(VR) models during operative planning.
Design, Setting, and Participants
A single-blind randomized clinical trial was performed. Ninety-two patients undergoing robotic-assisted partial
nephrectomy performed by 1 of 11 surgeons at 6 large teaching hospitals were prospectively enrolled and
randomized. Enrollment and data collection occurred from October 2017 through December 2018, and data analysis
was performed from December 2018 through March 2019.
Interventions
Patients were assigned to either a control group undergoing usual preoperative planning with computed tomography
and/or magnetic resonance imaging only or an intervention group where imaging was supplemented with a 3-D VR
model. This model was viewed on the surgeon’s smartphone in regular 3-D format and in VR using a VR headset.
Main Outcomes and Measures

The primary outcome measure was operative time. It was hypothesized that the operations performed using the 3-D
VR models would have shorter operative time than those performed without the models. Secondary outcomes
included clamp time, estimated blood loss, and length of hospital stay.
Results
Ninety-two patients (58 men [63%]) with a mean (SD) age of 60.9 (11.6) years were analyzed. The analysis included
48 patients randomized to the control group and 44 randomized to the intervention group. When controlling for case
complexity and other covariates, patients whose surgical planning involved 3-D VR models showed differences in
operative time (odds ratio [OR], 1.00; 95% CI, 0.37-2.70; estimated OR, 2.47), estimated blood loss (OR, 1.98; 95%
CI, 1.04-3.78; estimated OR, 4.56), clamp time (OR, 1.60; 95% CI, 0.79-3.23; estimated OR, 11.22), and length of
hospital stay (OR, 2.86; 95% CI, 1.59-5.14; estimated OR, 5.43). Estimated ORs were calculated using the parameter
estimates from the generalized estimating equation model. Referent group values for each covariate and the
corresponding nephrometry score were summed across the covariates and nephrometry score, and the sum was
exponentiated to obtain the OR. A mean of the estimated OR weighted by sample size for each nephrometry score
strata was then calculated.
Conclusions and Relevance
This large, randomized clinical trial demonstrated that patients whose surgical planning involved 3-D VR models had
reduced operative time, estimated blood loss, clamp time, and length of hospital stay.
Trial Registration
ClinicalTrials.gov identifiers (1 registration per site): NCT03334344, NCT03421418, NCT03534206, NCT03542565,
NCT03556943, and NCT03666104

Introduction
Kidney surgery, specifically robotic-assisted partial nephrectomy (RAPN), is an ideal case to test methods for surgical
planning other than the current standard of care, which typically involves review of computed tomography (CT) and
magnetic resonance imaging (MRI) scans. Localized renal masses are a rapidly growing subset of cancer, with the
incidence of stage I disease increasing from 3.7 to 7.0 cases per 100 000 US adults in the past decade.1 Although
treatment strategies such as surveillance and ablation have gained popularity of late, surgical intervention, specifically
RAPN, is the established standard for kidney cancer that is amenable to nephron-sparing approaches.2,3,4,5,6,7
Successfully performing this surgery depends largely on the surgeon’s understanding of the patient’s anatomy,
including the configuration of the kidney, mass, vessels, and collecting system.
Recent work8,9 has studied the impact of 3-dimensional (3-D) digital imaging on surgical planning for RAPN. Threedimensional imaging has been shown to improve understanding of patient anatomy, influence RAPN surgical plans,
and increase the use of selective clamping of renal arterial branches during RAPN.8,9 Although the previous work
validated that 3-D imaging provides meaningful additional information that affects understanding and surgical
planning, it remains unclear whether the use of patient-specific 3-D virtual reality (VR) models for operative planning
would also affect key surgical outcomes.
In this context, we identified patients undergoing RAPN and performed a multi-institutional, single-blind,
randomized clinical trial using 3-D VR models generated from CT or MRI scans. We sought to determine whether the
use of these patient-specific 3-D VR models for operative planning would affect key surgical outcomes.

Methods
Participant Eligibility
Participants were recruited from 6 large teaching hospitals. Patients with a solitary kidney, more than 1 ipsilateral
tumor, a planned bilateral operation, or who lacked preoperative imaging or were unable to give informed consent
were excluded from the study. There were no exclusions based on CT or MRI slice thickness. Participants signed a
written informed consent document that outlined the specific risks and benefits of enrollment. The study was
approved by the Western Institutional Review Board, which served as the institutional review board of record for 4

study sites. At 2 sites, the study was approved by the site’s own institutional review boards. This trial followed the
Consolidated Standards of Reporting Trials (CONSORT) reporting guideline (Figure 1). The trial protocol is shown
in Supplement 1.
Randomization, Blinding, and Sample Size
Patients consented to be randomized to either a control group, in which the operation was planned with surgeon
review of the CT and/or MRI scans only, or the intervention group, in which the surgeon reviewed both the CT and/or
MRI scans along with a 3-D VR model of the patient’s anatomy that was created by the sponsor from the source CT
and/or MRI scan. Randomization was stratified by surgeon experience, and each surgeon-specific randomization
schedule yielded a randomization in a 1:1 ratio per surgeon. Eleven surgeons participated in the study. Sequentially
numbered, opaque, sealed envelopes containing the treatment assignment for a single case were prepared by the
sponsor and provided to each site. Patients were assigned to a study group by opening an envelope at the time of
enrollment and were blinded to group assignment.
We calculated the sample size according to our pilot data,10 which showed a significant improvement in operative
time when 3-D VR models were using in surgical planning. In the pilot study,10 we noted an effect size of 0.44
regarding the difference in operative time between 3-D VR model–aided and control groups. We used data from the
variable of most interest, total operative time. We accounted for within-sample clustering and took 3 values of withincluster correction (ρ = 0.3, 0.5, and 0.7) to consider low, moderate, and high levels, respectively, of within-cluster
correlation. To account for multiple end points and some other unpredictable factors, we increased the sample size by
15%. We selected ρ = 0.3 given the wide variation in case complexity seen in our pilot study,10 which drastically
limited within-cluster clustering.
Model Preparation, Delivery, and Use
The CT or MRI scans from patients randomized to the intervention group were deidentified, provided to the sponsor
in Digital Imaging and Communications in Medicine format, and used to create a patient-specific 3-D VR model for
each intervention patient (Reveal software versions 2.1-2.3; Ceevra). This model included, at a minimum, the kidney,
mass, renal artery, and renal vein. Most models also included additional anatomic structures, such as the spleen,
splenic artery, splenic vein, ureter and collecting system, renal cysts (if present), ribs, and spine. In rare cases,
structures such as the psoas muscle or liver were included if there was any suspicion of tumor involvement of these
structures (eFigure in Supplement 2).
Surgeons reviewed the 3-D VR models via a mobile application developed by the sponsor and installed on their
smartphones. Parameters such as number of arteries and veins and nephrometry score with individual components
were also viewable from the surgeon’s smartphone. The model could be rotated and zoomed using standard
smartphone gestures, and the surgeon could show or hide each anatomic structure during the viewing session. In
addition, certain structures were rendered translucent to allow viewing of embedded structures. This was an important
feature to allow visualization of the mass within the kidney and, in some cases, cystic components of the mass.
For each intervention case, the surgeon viewed the 3-D VR model before the operation in both regular 3-D format
from the smartphone and in VR with an off-the-shelf Google Cardboard–compatible VR headset. Intraoperative
viewing of the 3-D VR models was performed at the surgeon’s discretion.
End-Point Selection and Data Collection
Enrollment and data collection occurred from October 2017 through December 2018. Demographic data, including
age, sex, and race, were collected for both groups from the medical record. Clinical data collected included site,
surgeon, surgeon experience level, resident or fellow involvement in the surgery, mass size, nephrometry score with
individual components, and laterality of operation. Operative data collected included transperitoneal or
retroperitoneal approach, use of intraoperative ultrasonography, and use of the fourth robotic arm. The nephrometry
score uses the tumor’s radius, endophyticity, nearness to the collecting system, and location to describe the tumor and
was used as a measure of case complexity.11,12 We identified outcome measures of interest from recent literature13,14
comparing robotic and laparoscopic partial nephrectomy. These outcomes had previously been investigated in the
pilot study.10 Our primary outcome measure (operative time) and secondary outcome measures (clamp time [ie, warm
ischemia time], estimated blood loss [EBL], and length of hospital stay) were collected from the medical record.

Operative time was defined as incision to closure, clamp time was the total time the renal vessel(s) were clamped,
EBL was estimated collaboratively by the surgeon and anesthesiologist, and discharge on postoperative day 1 was
recorded as a hospital stay of 1 day. We also recorded conversion to radical nephrectomy, conversion to open surgery,
margin status, intraoperative complications, postoperative complications, readmissions, and mortality.
Statistical Analysis
Data analysis was performed from December 2018 through March 2019. As an initial analytic step, we compared
baseline characteristics between cases performed with (intervention) or without (control) 3-D VR models involved in
preoperative planning. We used a nonparametric test (Wilcoxon rank sum test and median test) to compare
nonnormally distributed operative time, clamp time, and EBL means and medians. We also dichotomized the
outcomes as follows: less than or equal to the 75th percentile (low) vs greater than the 75th percentile (high) for
operative time and EBL, less than or equal to 20 minutes vs longer than 20 minutes for clamp time, and less than or
equal to 2 days vs longer than 2 days for hospital stay. In addition, we dichotomized length of hospital stay as less
than or equal to 1 day vs greater than 1 day to assess the earliest possible discharge. These cutoffs were chosen as
either having data-demonstrated adverse outcomes above the cutoff (clamp time), empirically near the standard for
our surgeon sample (hospital stay), or as a measure of surgical quality (operative time and EBL).15,16 We compared
the high vs low dichotomized outcome variables by group using a χ2 test.
For the multivariate analyses, we conducted a logistic regression for the dichotomous outcome measures, with group
as the main independent variable and intervention as the reference group. We included nephrometry score and
conducted a forward selection process, resulting in a model controlling for significant demographic and clinical
variables. We then conducted a multilevel model with the addition of the surgeon to control for findings clustering
around individual surgeons. From the resulting model, we calculated estimated odds ratios (ORs) for each outcome at
any given nephrometry score, as well as a weighted mean OR across all nephrometry scores. We calculated the
estimated ORs using the parameter estimates from the resulting generalized estimating equation model (PROC
GENMOD with REPEATED statement in SAS statistical software version 9.4 [SAS Institute]). We entered the
referent group value for each covariate (ie, “intervention” for group, “female” for sex, “none” for experience, “yes”
for fellow involvement, “left” for side, and mean of 61.5 years for age) and the corresponding nephrometry score into
the linear equation, summed across the covariates and nephrometry score, and exponentiated the sum to obtain the
OR. This was all calculated in SAS using the ESTIMATE statement. For each outcome, we also calculated a
weighted mean of the estimated OR weighted by sample size for each nephrometry score strata. All statistical tests
were 2-sided and were performed at the 5% significance level, using SAS.

Results
Ninety-two patients (58 men [63%]; mean [SD] age, 60.9 [11.6] years) were included in the analysis, with 48
randomized to the control group and 44 randomized to the intervention group. Baseline characteristics were well
matched between groups with the exception of higher mean (SD) age for the control group (64.6 [9.7] years vs 57.6
[12.3] years) (Table 1). Unadjusted mean (SD) values for operative time between control and intervention groups
(172.6 [48.5] minutes vs 173.3 [49.6] minutes; P = .70), clamp time (18.0 [7.9] minutes vs 17.6 [7.8] minutes; P
= .76), EBL (124.5 [90.5] mL vs 145.7 [140.4] mL; P = .71), and length of stay longer than 2 days (4 of 44
participants [9%] vs 7 of 48 participants [15%]; P = .41) showed no significant differences (Table 2).
In the subsequent multilevel model, patients in the control group were significantly more likely than patients with 3D VR–assisted surgical planning to have a length of stay longer than 2 days (OR, 2.86; 95% CI, 1.59-5.14) and EBL
greater than 200 mL (OR, 1.98; 95% CI, 1.04-3.78). Operative time (OR, 1.00; 95% CI, 0.37-2.70) and clamp time
(OR, 1.60; 95% CI, 0.79-3.23) were also examined but were not statistically different between groups in this model.
Some secondary covariates also were significant for the outcomes, including surgeon experience (OR for clamp time,
5.22; 95% CI, 1.86-14.6) and side of operation (OR for EBL, 3.53; 95% CI, 2.05-6.10) (Table 3). The estimated ORs
showed improvements in operative time (estimated OR, 2.47), EBL (estimated OR, 4.56), clamp time (estimated OR,
11.22), and hospital stay (estimated OR, 5.43) in the 3-D VR–assisted cases, as well as the association between case
complexity and the odds of more adverse outcomes if standard CT or MRI surgical planning was used (Figure 2).

Discussion

Cancer care over the last decade has evolved in both the surgical and medical arenas. From the surgical perspective,
minimally invasive approaches have gained popularity. Although laparoscopy set the stage, a major acceleration has
occurred with the advent of robotic-assisted systems, which enable many procedures to be performed without an open
incision and provide the surgeon with better visibility of the operating field and finer dexterity.17
Robotic-assisted partial nephrectomy is an ideal case study to assess the advantages and disadvantages of novel forms
of surgical planning because it is a complex operation, with many decision points being made according to the
patient’s anatomy, as understood by the surgeon from review of the patient’s CT or MRI scan. The decisions could
include, for example, whether to use a transperitoneal or retroperitoneal approach, selection of blood vessels for
clamping, identification of appropriate vessels to ligate (if any), and tumor resection margin and depth. In this
context, novel forms of surgical planning, such as those involving 3-D VR models, could help improve the surgeon’s
understanding of the patient’s anatomy and optimal surgical approach.
For patients undergoing RAPN, we identified the metrics that define a successful surgery, including operative time,
EBL, clamp time, and length of hospital stay. Operations that fare better according to these metrics are positively
correlated with better patient outcomes. Higher rates of 30-day perioperative complications have been seen in cases
with longer operative times and higher levels of EBL, both for RAPN and other types of operations.18,19,20 Shorter
clamp times and selective clamping can reduce the level of nephron loss due to hypoxia.21 Finally, shorter hospital
stays limit the potential for various in-hospital complications sometimes seen among patients undergoing RAPN.22,23
In this setting, our study has several important findings.
After controlling for the appropriate covariates for each outcome, the outcomes improved with the use of a 3-D VR
model. We further observed that the outcomes of our control group were consistent with previously published data14
for RAPN, adding validity to these findings.
We also saw that as case complexity increased, so too did the magnitude of the outcomes improvements. A previous
study24 indicated that complex cases are more likely than less complex ones to have adverse outcomes, both short
and long term. The management of the renal hilum is particularly challenging in cases with large central tumors, and
complex vascular anatomy may also lend an increased degree of difficulty to such cases. By clearly revealing the
relationships among these structures, including size, distance, and configuration, the 3-D VR models appeared to help
surgeons make improved preoperative decisions and may have helped minimize intraoperative challenges that occur
as a result of uncertain anatomic parameters in highly complex cases.
As context for these findings, it is worth examining the human visual processing system, which is sophisticated yet
highly dependent on cues to visualize 3-D spatial relationships.25 The 3-D VR application used in this study is
understood to have enhanced both 3-D visualization, which is dependent on cues such as linear perspective,
occlusion, shading, texture, and recognition of familiar structures. It would also have contributed to 3-D sensation,
with VR simulating cues such as motion parallax (ie, foreground objects appear to move faster than background
objects) and binocular disparity (ie, the difference in an image location between the right and left eyes).26 The study
results imply that understanding of patient anatomy was enhanced by 3-D VR models in the intervention cases,
which, in turn, may have contributed to the improvements seen in outcomes.
The 3-D VR models also may have reduced the cognitive load demanded of surgeons. The 3-D VR models simply
reduced the amount of information that the surgeon needed to process. The psychophysiological factors associated
with perception and interpretation of medical images have been studied extensively in the setting of radiologists’
reading of images to better understand sources of observer error; many of these factors, including the amount of
extraneous information that the radiologists visually absorb during reviews, are likely to affect surgeons’ cognition
during their own interpretation of imaging.27,28,29 Specifically, CT and MRI scans depict every element of the
patient’s anatomy captured during the imaging process, including those irrelevant to surgical decision-making. Those
cross-sectional images are visualized in gray scale, which communicates a wealth of detail requiring interpretation.
The 3-D VR models, in contrast, excluded structures that were less relevant to the operation. Although subtle
differences in voxel intensity on gray-scale CT and MRI scans aid radiological primary diagnosis, surgical planning
may be improved by a deeper understanding of the borders and shapes of structures, the junctions between them, and
the relationships between structures.30 These aspects are easily visualized in the 3-D VR models’ multicolor,
multitexture format.

Limitations
Our study has several limitations. First, we used nephrometry score as a proxy for case complexity, which assumes
that nephrometry scores are a reliable measure of technical difficulty. Nephrometry scores have been used to reliably
stratify the complexity of cases, and higher nephrometry scores have previously been associated with greater EBL,
warm ischemia time, overall operative time, and length of stay.11,12,31 However, other factors affecting case length
and complexity, including body mass index, prior abdominal or retroperitoneal surgery, and the presence of sticky fat,
are not captured in the nephrometry score. Second, 11 surgeons, with varying levels of robotic experience and
assistance in the operating room, were involved in this study. However, we controlled for this in our analysis by
controlling for both the experience level of the surgeon and the presence of a resident or fellow in the operating room.
In addition, the use of a multilevel model also helped to address the issue of within-surgeon correlations. Third, we
made multiple comparisons in our analysis, which increases the probability of generating a significant result.
However, the careful selection of end points to correlate with both the hypothesized benefits of the model and the
relatively small number of end points limit the chance of this issue. Fourth, the loss of 7 patients from our analysis
may have affected our overall results.

Conclusions
Our findings may affect the care of patients undergoing RAPN in several ways and have the potential to change the
way preoperative planning is performed altogether. The patient, physician, and hospital may all derive benefit from
this technology, each in a different way. For patients, this benefit comes by way of improved outcomes. The 3-D VR
models augment the surgeon’s ability to deliver excellent surgical care by addressing key limitations in the current
surgical planning process. Hospitals will benefit from both reduced operative time and shortened patient length of
stay. To improve the ability to deliver this care to patients at a population level, future work should focus on process
workflows and integration to ensure that surgeons have a simple, seamless way to obtain 3-D VR models for surgical
planning. Also, although this technology is clearly useful for kidney surgery, it may also improve the outcomes of
patients needing surgical interventions for many other conditions.

Notes

Supplement 1.

Trial Protocol

Supplement 2.

eFigure. Computed Tomography Scan of Kidney and Mass With Corresponding 3-Dimensional, Virtual
Reality Model

Supplement 3.

Data Sharing Statement
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Figure 1.

Open in a separate window
Flow of Participants in the 3-Dimensional Virtual Reality Models for Surgical Planning of Robotic-Assisted Partial
Nephrectomy Trial
DICOM indicates Digital Imaging and Communications in Medicine.

Table 1.
Baseline Characteristics Between Groups Who Underwent Robotic-Assisted Partial Nephrectomy With
and Without 3-Dimensional Virtual Reality Models
Characteristic

Participants, No. (%)
Virtual Reality Models (n

No Virtual Reality Models (n

= 44)

= 48)

64.6 (9.7)

57.6 (12.3)

Male

29 (66)

29 (60)

Female

15 (34)

19 (40)

White

36 (82)

38 (79)

Nonwhite

8 (18)

10 (21)

4

5 (11)

11 (23)

5

3 (7)

6 (12)

6

3 (7)

8 (17)

7

5 (11)

8 (17)

8

8 (18)

8 (17)

9

13 (30)

4 (8)

10

5 (11)

2 (4)

11

2 (5)

1 (2)

1-10

4 (9)

8 (17)

11-30

7 (16)

7 (15)

>30

33 (75)

33 (69)

Fellow involved in operation

25 (57)

25 (52)

Resident involved in operation

22 (40)

26 (54)

Right

26 (59)

20 (42)

Left

18 (41)

28 (58)

Retroperitoneal

8 (18)

14 (29)

Transperitoneal

36 (82)

34 (71)

Fourth robotic arm used

28 (64)

25 (52)

Age, mean (SD), y
Sex

Race

Nephrometry score

Surgeon experience with robotic-assisted partial nephrectomy,
No. of cases/y

Laterality

Approach

Open in a separate window

Table 2.
Comparative Outcomes Between Groups Who Underwent Robotic-Assisted Partial Nephrectomy With
and Without 3-Dimensional Virtual Reality Models
Outcome

Virtual Reality Models (n = 44) No Virtual Reality Models (n = 48) P Value

Operative time, min
Mean (SD)

172.6 (48.5)

173.3 (49.6)

Median (IQR)

163 (146.5-200.5)

173.5 (148.0-199.0)

a
.70
b
.10

c
>75th Percentile, participants, No. (%)

11 (25)

11 (23)

.82

Mean (SD)

18.0 (7.9)

17.6 (7.8)

Median (IQR)

18 (15-23)

18 (12-22)

a
.76
b
.90

c
>75th Percentile, participants, No. (%)

11 (25)

11 (24)

.90

>20 min, participants, No. (%)

14 (32)

16 (35)

.77

Participants, No.

41

43

Mean (SD)

19.3 (6.3)

18.8 (6.4)

Median (IQR)

18 (16-24)

18 (13-23)

a
.71
b
.97

c
>75th Percentile, participants, No. (%)

11 (27)

11 (26)

.90

Mean (SD)

124.5 (90.5)

145.7 (140.4)

Median (IQR)

100 (50-200)

100 (50-200)

c
>75th Percentile, participants, No. (%)

4 (9)

6 (12)

a
.71
b
.55
d
.74

Length of stay >2 d, participants, No. (%) 4 (9)

7 (15)

.42

Clamp time, min

Clamp time >0 min

Estimated blood loss, mL

Abbreviation: IQR, interquartile range.
a

Wilcoxon rank sum test of means.
Brown-mood test of medians.
c
The 75th percentiles are defined as follows: operative time, 199 minutes; clamp time, 22 minutes; and estimated blood loss, 200
mL.
d
Fisher exact test.
b

Table 3.
Comparative Outcomes Between Groups Who Underwent Robotic-Assisted Partial Nephrectomy With
and Without 3-Dimensional Virtual Reality Models, Mixed Model
Characteristic

Group (control vs

Odds Ratio (95% CI)
Operative Time >199

Clamp Time >22

Estimated Blood Loss >200

Length of Stay

min vs ≤199 min

min vs ≤22 min

mL vs ≤200 mL

2-5 d vs 1

3-5 d vs 1-

d

2d

1.79

2.86

(0.843.86)

(1.59b
5.14)

1.16

1.04

(1.06a
1.27)

(0.85-

NS

1.07

1.00 (0.37-2.70)

1.60 (0.79-3.23)

a
1.98 (1.04-3.78)

intervention)
Nephrometry score

Age

1.13 (0.77-1.65)

NS

a
1.29 (1.03-1.63)

NS

1.12 (0.82-1.53)

NS

1.28)
(1.01a
1.14)

a
2.20 (1.07-4.55)

NS

Side (right vs left)

NS

NS

Fellow (no vs yes)

NS

NS

b
3.53 (2.05-6.10)
a
3.70 (1.01-13.6)

b
5.22 (1.86-14.6)

NS

Sex (male vs

NS

NS

NS

NS

NS

NS

NS

NS

NS

female)

Surgeon experience NS

Abbreviation: NS, not sufficient (ie, the model did not yield sufficient data to report here).
a

P < .05.
P < .01.

b

Figure 2.

Estimated Odds Ratios for Outcomes With 3-Dimensional Virtual Reality Models, by Nephrometry Score
Estimated odds ratios were calculated using the parameter estimates from the generalized estimating equation model. Referent group
values for each covariate and the corresponding nephrometry score were summed across the covariates and nephrometry score, and the
sum exponentiated to obtain the odds ratio. A mean of the estimated odds ratio weighted by sample size for each nephrometry score
strata was then calculated. EBL indicates estimated blood loss; and LOS, length of stay.

